BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BC Innovations | Feb 6, 2019
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
BC Week In Review | Aug 24, 2015
Company News

Ember Therapeutics, Knight Therapeutics deal

Ember granted Knight exclusive rights to commercialize Ember’s bone morphogenetic protein 7 ( BMP7 ; OP-1) pipeline in Canada, Israel, Russia and sub-Saharan Africa. The lead product has completed a Phase IIa trial to treat osteoarthritis....
BC Week In Review | Mar 23, 2015
Company News

Ember Therapeutics, Mariel deal

Obesity and diabetes company Ember and Mariel, which is developing compounds targeting bone morphogenetic protein 7 ( BMP7 ; OP-1), will merge and form Ember Therapeutics Inc. The companies did not disclose financial terms and could...
BC Innovations | Aug 21, 2014
Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
BC Innovations | Aug 7, 2014
Targets & Mechanisms

Adipsin meets beta cells

The long-standing mystery of how adipsin regulates metabolism has been solved by a Harvard-led team that has shown the enzyme can increase insulin secretion by generating the peptide complement 3a . 1 Its therapeutic potential may...
BC Innovations | Jul 10, 2014
Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Obesity; inflammation Meteorin glial cell differentiation regulator-like (METRNL) Mouse studies suggest increasing METRNL signaling could help treat obesity and inflammatory diseases. In mice, an adenoviral...
BC Innovations | Jul 10, 2014
Cover Story

Going immune on beige fat

Since its founding in 2010, Ember Therapeutics Inc. has been exploiting the biology of brown and beige fat to treat metabolic diseases, including obesity and type 2 diabetes. Now, the biotech has an option to...
BC Innovations | May 2, 2013
Distillery Techniques

Technology: Markers

This week in techniques Approach Summary Licensing status Publication and contact information Markers Brown adipose tissue (BAT) in adult humans Two separate studies in humans identified physiological and genetic markers of BAT, which could aid...
BC Innovations | Jan 10, 2013
Cover Story

mAb about FGF21

Amgen Inc. has developed an antibody that mimics fibroblast growth factor 21 and has antidiabetic effects in monkeys. 1 The findings cap a year of advances that have greatly increased understanding of the protein's tissue-specific...
Items per page:
1 - 10 of 29
BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BC Innovations | Feb 6, 2019
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
BC Week In Review | Aug 24, 2015
Company News

Ember Therapeutics, Knight Therapeutics deal

Ember granted Knight exclusive rights to commercialize Ember’s bone morphogenetic protein 7 ( BMP7 ; OP-1) pipeline in Canada, Israel, Russia and sub-Saharan Africa. The lead product has completed a Phase IIa trial to treat osteoarthritis....
BC Week In Review | Mar 23, 2015
Company News

Ember Therapeutics, Mariel deal

Obesity and diabetes company Ember and Mariel, which is developing compounds targeting bone morphogenetic protein 7 ( BMP7 ; OP-1), will merge and form Ember Therapeutics Inc. The companies did not disclose financial terms and could...
BC Innovations | Aug 21, 2014
Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
BC Innovations | Aug 7, 2014
Targets & Mechanisms

Adipsin meets beta cells

The long-standing mystery of how adipsin regulates metabolism has been solved by a Harvard-led team that has shown the enzyme can increase insulin secretion by generating the peptide complement 3a . 1 Its therapeutic potential may...
BC Innovations | Jul 10, 2014
Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Obesity; inflammation Meteorin glial cell differentiation regulator-like (METRNL) Mouse studies suggest increasing METRNL signaling could help treat obesity and inflammatory diseases. In mice, an adenoviral...
BC Innovations | Jul 10, 2014
Cover Story

Going immune on beige fat

Since its founding in 2010, Ember Therapeutics Inc. has been exploiting the biology of brown and beige fat to treat metabolic diseases, including obesity and type 2 diabetes. Now, the biotech has an option to...
BC Innovations | May 2, 2013
Distillery Techniques

Technology: Markers

This week in techniques Approach Summary Licensing status Publication and contact information Markers Brown adipose tissue (BAT) in adult humans Two separate studies in humans identified physiological and genetic markers of BAT, which could aid...
BC Innovations | Jan 10, 2013
Cover Story

mAb about FGF21

Amgen Inc. has developed an antibody that mimics fibroblast growth factor 21 and has antidiabetic effects in monkeys. 1 The findings cap a year of advances that have greatly increased understanding of the protein's tissue-specific...
Items per page:
1 - 10 of 29